Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside |
| |
| Affiliation: | 1. Department of Biological Sciences, Vanderbilt University, Nashville, TN 37232, USA;2. Department of Biochemistry, Vanderbilt School of Medicine, Nashville, TN 37232, USA;3. Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA;1. UFRR/CCA, POSAGRO Doctor’s Program, BR174 Km12, 69310-270 Boa Vista, RR, Brazil;2. UFRR/CCA, Deptartment of Plant Science, BR 174 Km 12, 69310-270 Boa Vista, RR, Brazil;3. UFRR/POSAGRO, BR 174 Km 12, 69310-270 Boa Vista, RR, Brazil;4. UFRR, BR174 Km12, 69310-270 Boa Vista, RR, Brazil;5. UEL, Campus Universitário, Jardim Perobal, CEP: 8605-1990, Londrina, PR, Brazil |
| |
| Abstract: | Poly(ADP-ribose)polymerase (PARP) inhibitors are a novel class of anticancer agents that target the DNA damage response pathways. The enzyme target, PARP, plays a key role in signalling DNA single-strand breaks. Clinical development to date has focused on their potential role in combination with DNA-damaging chemotherapy, where efficacy has been limited by enhanced normal tissue toxicity, and as single agents in the context of synthetic lethality. This article reviews these data in the context of future development as radio-potentiating agents. |
| |
| Keywords: | Chemo-potentiation DNA damage response poly(ADP-ribose)polymerase (PARP) radio-potentiation synthetic lethality |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
